IMPORTANCE Amyloid-β is a major component of retinal drusen, the primary lesions of age-related macular degeneration (AMD), and autopsy and animal models suggested that anticholinergic drug (ACD) use increased brain amyloid-β deposition.
A ge-related macular degeneration (AMD) is the leading cause of vision loss in people 50 years and older in the developed world. [1] [2] [3] It is characterized by macular extracellular deposits (drusen) and degeneration of retinal pigmented epithelium and photoreceptors (with or without choroidal neovascularization). Pathogenic pathways mediating this development are discussed. Inflammation, hypoxia, and oxidative stress seem to have a central role. 3, 4 Several risk factors of AMD have been identified, aging being the strongest. Other major risk factors are smoking (with a reversibility of the risk after cessation) and family history of AMD (some genetic markers have been identified). Further risk factors show a moderate strength of association: previous cataract surgery, high body mass index (BMI), other cardiovascular risk factors, history of cardiovascular disease, nutritional factors (protective action of antioxidants, lutein, and ω3), sunlight exposure, and iris color. 3, 5 No drug use has been clearly associated with the occurrence of AMD. The protective effect of statins 6 and antiinflammatory drugs use is uncertain. 7, 8 Medications suspected to increase AMD risk are aspirin, 9 thyroxin, 10 and β-blockers. 11, 12 Bias relating this drug use to patients' medical history could not be excluded.
Older adults frequently use medications with anticholinergic activity (prevalence from 7.5% to 27%), [13] [14] [15] [16] but panels of experts have suggested that the benefits of these agents in older populations may be surpassed by the risks. 17,18 Some anticholinergic drugs (ACDs) achieve the intended therapeutic effect by blocking the effect of acetylcholine at the muscarinic receptor within specific organ systems (eg, bladder antimuscarinics, bronchodilators, and anti-Parkinson agents). However, other medications have unintended anticholinergic effects that are not the primary therapeutic activity (eg, first-generation antihistamines, tricyclic antidepressants, and some antipsychotic agents). Anticholinergic drug use has been associated with cognitive decline and dementia, [13] [14] [15] [19] [20] [21] [22] and reduced cholinergic transmission is suspected to increase brain amyloid-β deposition. [23] [24] [25] [26] Additionally, cognitive impairment has been associated with AMD, 27-30 and characteristic lesions of AMD (drusen) and Alzheimer disease (senile plaques) both contain amyloid-β deposits, 31-33 suspected to contribute to local inflammation and oxidative stress leading to retinal degenerative events in AMD. [34] [35] [36] [37] [38] [39] The aim of this study was to explore the association between ACD use and late AMD occurrence.
Methods

Study Design and Setting
This multicenter case-control study followed the 
Participants
Participants were enrolled from July 2016 to June 2017. Eligible case participants were defined as any person consulting for late AMD, already diagnosed or not, defined by feature of neovascular AMD (nAMD) with active or inactive choroidal neovacularisation, or geographic atrophy (GA) or the retinal pigment epithelium, in at least 1 eye confirmed by an ophthalmologist. Control participants were selected among people older than 60 years who were consulting in the same centers during the same period for refraction assessment but without ophthalmologic disease as confirmed by a detailed ophthalmic examination. Patients with early AMD (large drusen or pigment abnormality) were not included in this study.
Data Sources/Measurements
Age-Related Macular Degeneration History Age at late AMD diagnosis and at the beginning of neovascular complications for each eye were from medical files and patient questioning. The index date was defined as the late AMD diagnosis date in cases and as the inclusion date in controls.
Drug Exposure
All drug exposures throughout life, for at least 3 months, and starting before the index date were recorded, with specific recording of ACDs; benzodiazepines; antihypertensive drugs; statins; fibrates; anti-aggregate, anticoagulate, and antiinflammatory drugs; levothyroxine; and amiodarone. We specifically questioned patients and relatives accompanying them during an interview, relying on a questionnaire listing all drugs (classified by indication) and on medical prescriptions from a general practitioner. 45 The included drugs with their corresponding Anticholinergic Drug Scale score are listed in the eTable in the Supplement. Ever exposure to ACDs was defined as use of at least 1 of these drugs throughout the lifetime, for at least 3 months, and starting before the index date. Previous exposure was defined as use discontinued before AMD diagnosis, and current exposure was defined as use ongoing at AMD diagnosis.
Anticholinergic Burden Score
To assess a dose-effect association, we calculated the Anticholinergic Burden Score for each patient as described by Moulis et al 41 by summing the Anticholinergic Drug Scale score for all ACDs ever used. 42 For drugs marketed in France not listed in the Anticholinergic Drug Scale, we attributed the same anticholinergic weight as that assigned by a college of pharmacologists in previous French studies. 41, 43 The Anticholinergic Burden Score was classified as 0, 1 to 2, and at least 3, with cut points based on previous studies 41 and on the distribution observed in our sample. This indicates low, medium, and high burden.
Cumulative Exposure Duration
Age at onset and exposure duration to each ACD before AMD diagnosis were recorded. We calculated the cumulative exposure duration to ACDs by summing the exposure duration of all ACDs ever used before AMD diagnosis. Cumulative exposure duration was classified as no use and use for less than 5, 5 to 15, and more than 15 years, with cut points based on clinical interpretability and on the distribution observed in our sample.
Covariates From a literature review, we selected covariates that may confound the relation between ACD use and late AMD. 3, 5 Age, sex, college education level, race/ethnicity, eye color, and first-degree family history of AMD were identified. Body mass index was calculated as weight in kilograms divided by height in meters squared, with overweight defined as between 25 and 30 and obesity defined as more than 30.
Smoking at the index date was classified as nonsmoker, ex-smoker, or current smoker. Alcohol intake was classified as nondrinker, rare drinker (<1 units/d), moderate drinker (1-2 units/d), and excessive drinker (≥3 units/d). Data on fruits, vegetables, fish, red meat, and poultry consumption by week were collected. We also recorded the presence of the following potential confounding factors: high blood pressure, diabetes (types 1 and 2), hyperlipidemia, coronary artery disease, cerebrovascular disease, peripheral vascular disease, cataract surgery, and known memory disorders with significant effect on everyday life. We identified medical indications associated with ACD use such as major depressive episode, Parkinson disease, and epilepsy. Only diagnoses made before the index date were included in the analyses.
Statistical Analysis
Descriptive statistics were used to summarize the baseline characteristics of cases and controls. In the primary analysis, to assess the association between AMD and ever exposure to ACDs, we calculated odds ratios (ORs) with 95% CIs by using a logistic regression model adjusted for sex, age, and other risk factors for AMD that were known (eg, smoking status and AMD family history) or identified in our analyses (alcohol consumption and use of anticoagulant and anti-inflammatory drugs), estimating adjusted ORs (aORs) and 95% confidence intervals. In a secondary analysis, we used the same model to assess the association between AMD and current exposure to ACDs, previous exposure to ACDs, cumulative exposure duration to ACDs, and Anticholinergic Burden Score. Third, we performed subgroup analyses by unilateral or bilateral AMD, GA, or nAMD. Assuming a prevalence of ACD use of 7.5% in the older population 15 and a clinically significant OR of 2.5, with a statistical power of 80% and a risk of error of 5%, we estimated a sample size of at least 382 people (191 cases and 191 controls). Analyses involved use of SAS, version 9.2 (SAS Institute Inc). P values were 2-sided and were considered significant at a level of .05.
Results
Population Description
A total of 200 cases and 200 controls were included. Characteristics of cases and controls are listed in Table 1 . The number of women was 129 (64.5%) and 116 (58%), respectively. At the index date, the mean (SD) age was 74.8 (9.2) years and 75.5 (7.2) years, respectively, with a slightly higher prevalence of age 70 to 80 years for controls. At the index date, 65 cases (32.5%) had GA, 135 (67.5%) had nAMD, 116 (58%) had unilateral AMD, and 84 (42%) had bilateral AMD. Compared with controls, cases were more likely than controls to be current smokers (OR, 2.09; 95% CI, 1.13-3.87; P = .02), be overweight (OR, 1.61; 95% CI, 1.04-2.49; P = .03), and have a first-degree family history of AMD (OR, 2.88; 95% CI, 1.55-5.33; P = .001); they were less likely to be moderate drinkers (OR, 0.42; 95% CI, 0.24-0.74; P = .003). Other characteristics did not differ between the groups.
ACD Exposure and Dose-Response Relation
Overall, 26 cases (13%) vs 10 controls (5%) were ever exposed to ACDs ( Table 2) . Risk of late AMD was increased with ever use of ACDs (OR, 2.84; 95% CI, 1.33-6.06; P = .007), which remained after adjustment for age, sex, smoking status, AMD family history, alcohol consumption, and use of anticoagulant and anti-inflammatory drugs (aOR, 2.39; 95% CI, 1.07-5.33; P = .03). The most common ACD classes used were antidepressants (15 cases [7. 5%] and 7 controls [3.5%]). Compared with never use of ACDs, current and previous ACD use were not associated with AMD (aOR, 2.22; On stratifying analyses by AMD subclasses (Table 3) , ever exposure to ACDs was associated with increased risk of GA (OR, 3.46; 95% CI, 1.37-8.73; P = .009), nAMD (OR, 2.56; 95% CI, 1.12-5.82; P = .03), and bilateral and unilateral AMD (OR, 2.86; 95% CI, 1.17-7.03; P = .02 and OR, 2.82; 95% CI, 1.22-6.51; P = .02).
Exposure to Drugs Other Than ACDs
Risk of AMD was reduced with use of anticoagulant and steroidal anti-inflammatory drugs (OR, 0.32; 95% CI, 0.11-0.89; P = .03 and OR, 0.26; 95% CI, 0.07-0.95; P = .04). The groups did not differ in other drug classes used ( Table 4) .
Discussion
This case-control study revealed an association of late AMD with ever exposure to ACDs for at least 3 months before AMD diagnosis. The association was observed after adjustment for the main AMD risk factors known or identified in our analyses. A dose-effect relation was observed, with a greater association of AMD with long cumulative ACD exposure and high Anticholinergic Burden Score.
ACD List Choice
Among the different ACD lists and scales available, we chose the methods of Moulis et al 41 : we restricted the Anticholinergic Drug Scale 42 to drugs with clinical antimuscarinic effects consensually accepted (using the list from Durán et al 44 ) and added the drugs with clinical antimuscarinic effects marketed in France (using the list from Laroche et al). 45 The Anticholinergic Risk Scale 46 is debatable in geriatrics studies because it does not include some ACDs widely used in older patients. 47 Finally, the Anticholinergic Cognitive Burden scale 48 overestimates the anticholinergic clinical effect of drugs such as paroxetine and olanzapine. 47 It does not include some drugs with clinical anticholinergic effects such as fluoxetine 47 ; therefore, it was not appropriate for our purpose. We chose to collect exposure for at least 3 months because of the difficulty for patients to remember medications used for a short time and because of the inability of previous studies to show adverse effects for cognitive function of ACD intake for less than 3 months.
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Pathophysiological Hypothesis
Several mechanisms may be suggested to explain the association of ACD use and AMD. One is the increase in macular inflammation owing to retinal amyloid-β deposition secondary to ACD use. Anticholinergic drug use is suspected to increase brain amyloid-β deposition. An autopsy study of patients with Parkinson disease found increased levels of Alzheimer disease neuropathologic features in participants who used ACDs for 2 years or longer. 23 Moreover, in animal Additionally, exposure of retinal pigment epithelium to ultraviolet radiation may be increased via mydriasis induced by ACDs. The association of ultraviolet radiation exposure and late AMD has been studied, [49] [50] [51] but to our knowledge, not that of pupil size and AMD.
Anticoagulant Drugs
We observed a lower rate of AMD among patients using anticoagulant drugs, which was not previously described in the literature. The finding may be explained by the reduced activity of factor Xa and thrombin, which are suspected to stimulate proinflammatory and profibrotic mediator production by retinal pigment epithelial cells. 52 We also observed a lower rate of AMD among patients using antiinflammatory drugs, which was previously described 7 but
with conflicting results. 8 
Strengths and Limitations
The data concerning covariates and exposure to ACDs were self-reported, which suggests potential recall bias in this study and possible underestimation of ACD use. However, these data were assessed similarly in cases and controls. Anticholinergic drug use in controls was lower than in previous studies [13] [14] [15] [16] probably because these studies considered an older population and shorter use as well as topical use (eg, bronchodilatators) and drugs with in vitro anticholinergic effects only.
Age at GA onset is sometimes difficult to determine accurately, which raises some concern in the temporal association of ACD and GA. We observed a higher association between ACD and nAMD with a lower risk of temporal bias than in GA.
Cases were representative of the AMD population, with similar diagnostic age and proportion of GA and nAMD 53 and the same exposure to the main other risk factors (OR between 2 and 3 for AMD family history and current smoking). Concerning other covariates, such as medical indications associated with ACD use, including major depressive syndrome, controls were similar to cases. Moreover, ACD use was the only medication recorded in this study associated with increased risk of AMD. Therefore, a selection bias of controls is unlikely. The case-control design of this study did not allow for assessing a causative relation. We were not able to assess the risk reduction or persistence after discontinuation of ACDs. There were no other investigations than anticholinergic association with AMD, which was the primary objective of this prospective study. The case-control design of this study did not allow for assessing a temporal association. Moreover, consistency of this association cannot be affirmed by other studies, and because AMD is permanent, we cannot look for reversibility. Therefore, beyond the strength of the association and the doseeffect relation suggested, we cannot affirm a causative relation.
Conclusions
This study suggests an association of late AMD with ACD use for at least 3 months. A dose-effect relation was suggested by a greater association with prolonged intake and high Anticholinergic Burden Score. Further studies are needed to confirm this association and assess potential causative pathways between ACD use and late AMD. 
